Observational studyInternational journal of surgery (London, England)2025
The development and validation of a risk stratification system for assessing axillary status after neoadjuvant therapy in node-positive breast cancer: a multicenter, prospective, observational study.
Observational study in International journal of surgery (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Beyond pCR Prediction: Subtype-Specific Artificial Intelligence for Treatment Tailoring in Breast Cancer Neoadjuvant Therapy.Cancers · 2026Review
- Comment on "The development and validation of a risk stratification system for assessing axillary status after neoadjuvant therapy in node-positive breast cancer: a multicenter, prospective, observational study".International journal of surgery (London, England) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveIt is not clear which procedure is most optimal for axilla after neoadjuvant therapy (NAT) in node-positive breast cancer patients. Accurately identifying patients with axillary pathologic complete response (pCR) is crucial to minimize the overtreatment of axilla. This study was designed to develop a risk stratification model for axillary pCR.
methodsIn this multicenter, prospective, observational study, node-positive breast cancer patients who received NAT followed by axillary lymph node dissection (ALND) were enrolled between June 2021 and April 2024. We assessed the performance of breast shear wave elastography (SWE) utilizing virtual touch imaging quantification in determining axillary status across ultrasound (US) nodal stages following NAT. A predictive model incorporating axilla US nodal stage and breast SWE was developed using multivariate logistic regression analysis. Last, a simplified risk score was developed based on the calculated prediction probability from this model and validated in the external test cohort.
resultsThe axillary pCR rates were 52.53% in the training cohort ( n = 257) and 51.79% in the external test cohorts ( n = 195). Approximately 21.67% of US N0 cases were false negatives; 42.35% of US N1 cases were false positives. With SWE, the false negative rate was 11.53% in US N0 patients and false positive rate was 22.22% in US N1 patients. The model based on dual-modality US demonstrated strong discriminatory ability (AUC, 0.93), precise calibration (slope of calibration curve, 0.99), and practical clinical utility (probability threshold, 4.5-94.5%); the percentages of accuracy, sensitivity, and specificity were 87.94%, 88.52%, and 87.41%, respectively. Patients scoring 1 demonstrated a low axillary non-pCR rate (5.21%-6.97%), potentially reducing unnecessary ALND rate (17.12%-24.10%).
conclusionsThe risk stratification model integrating axilla US and breast SWE demonstrated good performance for assessing axillary status after NAT in node-positive breast cancer and might provide guidance for less aggressive management for specific individuals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.